{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:41:44Z","timestamp":1776728504548,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cllc.2025.10.003","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:30:05Z","timestamp":1760221805000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and\/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24)"],"prefix":"10.1016","volume":"27","author":[{"given":"Miso","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeonghwan","family":"Youk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":false,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.10.003_bib0001","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U","article-title":"Pleomorphic (spindle\/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases","volume":"73","author":"Fishback","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2025.10.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2012.05.007","article-title":"Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis","volume":"152","author":"Yendamuri","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.cllc.2025.10.003_bib0003","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2007.05.006","article-title":"Palliative chemotherapy for pulmonary pleomorphic carcinoma","volume":"58","author":"Bae","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.10.003_bib0004","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cllc.2016.03.001","article-title":"Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung","volume":"17","author":"Ung","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2025.10.003_bib0005","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/01.JTO.0000437008.00554.90","article-title":"Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma","volume":"8","author":"Vieira","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.10.003_bib0006","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/ajco.13460","article-title":"Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma","volume":"17","author":"A\u011fa\u00e7k\u0131ran","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.10.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2015.08.013","article-title":"Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas","volume":"51","author":"Kim","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2025.10.003_bib0008","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1038\/s41467-020-18702-3","article-title":"Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma","volume":"11","author":"Yang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2025.10.003_bib0009","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.01.014","article-title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma","volume":"15","author":"Domblides","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.10.003_bib0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2020.03.029","article-title":"Outstanding clinical efficacy of PD-1\/PD-L1 inhibitors for pulmonary pleomorphic carcinoma","volume":"132","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2025.10.003_bib0011","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1111\/1759-7714.13684","article-title":"Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07","volume":"11","author":"Kim","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2025.10.003_bib0012","doi-asserted-by":"crossref","first-page":"S1002","DOI":"10.1016\/j.annonc.2021.08.1894","article-title":"1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603\/NCCH1703)","volume":"32","author":"Toyozawa","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.10.003_bib0013","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/JTO.0000000000000074","article-title":"Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC","volume":"9","author":"Champiat","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.10.003_bib0014","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lungcan.2018.06.009","article-title":"Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma","volume":"122","author":"Lee","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.10.003_bib0015","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.10.003_bib0016","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.10.003_bib0017","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.10.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105343","article-title":"Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis","volume":"10","author":"Amrane","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2025.10.003_bib0019","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4143\/crt.2023.764","article-title":"Genomic landscape of pulmonary sarcomatoid carcinoma","volume":"56","author":"Kwon","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.cllc.2025.10.003_bib0020","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1002\/cai2.112","article-title":"Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes","volume":"3","author":"Seth","year":"2024","journal-title":"Cancer Innov"},{"key":"10.1016\/j.cllc.2025.10.003_bib0021","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non\u2013small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:06:45Z","timestamp":1776726405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425002438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1525730425002438"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.10.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and\/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}